Skip to main content

Apogenix’ partner CANbridge announces 67 % five-year overall survival rate compared to 8.2 % in institutional database with asunercept plus standard of care in newly diagnosed glioblastoma multiforme patients

Written by Julia Bittner on . Posted in Client News.